Clicky

ACADIA Pharmaceuticals Inc.(ACAD) News

Date Title
Apr 22 Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Apr 17 Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
Apr 10 ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
Apr 2 Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
Apr 1 Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Mar 28 ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
Mar 14 3 Pharma Stocks to Sell in March Before They Crash & Burn
Mar 13 Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
Mar 12 Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study
Mar 11 UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study
Mar 11 Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
Jan 31 Acadia Announces Additions to Executive Team
Jan 30 20 Countries With The Highest Number of Drug Trafficking in the World
Jan 26 Best Drug and Alcohol Rehab Centers in Each of 30 Biggest Cities in the US
Jan 25 10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts
Jan 18 Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic
Jan 13 ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 3,732 Shares
Dec 21 Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Dec 18 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Fly 25% But Investors Aren't Buying For Growth
Nov 30 Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome